The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.
 
Eric Roeland
Honoraria - Pfizer
Consulting or Advisory Role - Eisai (Inst); Helsinn Healthcare (Inst); HERON; Napo Pharmaceuticals
Speakers' Bureau - Depomed; Eisai; Teva
Research Funding - AstraZeneca (Inst); Merck (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Eisai; Helsinn Healthcare; Teva
 
Gary Binder
Employment - Celgene; Helsinn Therapeutics
Stock and Other Ownership Interests - Celgene
 
Joseph Ma
Employment - Intercept Pharmaceuticals (I)
Stock and Other Ownership Interests - Amgen
 
Corinna Lanzarotti
Employment - Helsinn Healthcare
 
Li Zhang
Consulting or Advisory Role - MSD
Research Funding - Lilly; MSD